Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

557366 Rosiglitazone - CAS 155141-29-0 - Calbiochem

A thiazolidinedione compound that acts as an anti-diabetic agent and serves as a potent and selective agonist of peroxisome proliferator-activated receptor-γ (PPARγ) (Kd ~40 nM) in fat cells.

Rosiglitazone - CAS 155141-29-0 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, BRL49653, Avandia, PPAR Agonist X, PPARγ Agonist IX, AMPK Signaling Activator X

557366
Purchase on Sigma-Aldrich

Přehled

Replacement Information

Tabulka spec. kláve

CAS #Empirical Formula
155141-29-0C₁₈H₁₉N₃O₃S.C₄H₄O₄

Products

Katalogové čísloBalení ks/bal.
557366-10MG Skleněná láhev 10 mg
Description
OverviewA thiazolidinedione compound that acts as an anti-diabetic agent and serves as a potent and selective agonist of peroxisome proliferator-activated receptor-g (PPARg) (Kd ~40 nM) in fat cells. Shown to reduce fatty acid uptake and ameliorate lipid metabolism and insulin resistance in animal models of type II diabetes. Reported to activate both a1- and a2-containing AMPK complexes. Unlike troglitazone, it does not induce the activity of P4503A4. Significantly improves the differentiation of C3H10T1/2 stem cells into adipocytes. Shown to block estrogen synthesis by interfering with androgen binding to aromatase, but without affecting aromatase mRNA or protein expression.
Catalogue Number557366
Brand Family Calbiochem®
Synonyms5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, BRL49653, Avandia, PPAR Agonist X, PPARγ Agonist IX, AMPK Signaling Activator X
References
ReferencesAraki, T., et al. 2011. PPAR Res. 2011, 926438.
Sozio, M. S., et al. 2011. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G739.
Gerstein, H., et al. 2006. Drug 368, 9541.
Mohanty, P., 2004. Journ. Clin. Endocrin. & Metab. 89(6), 2728-2735.
Fryer, L., et al. 2002. J Biol Chem 277, 25226.
Goldberg, R., et al. 1999. Drug. 57, 921.
Young, P., et al. 1998. Journ. Pharm. Exp. Ther. 284, 751.
Willson, T., et al. 1996. J. Med. Chem.39, 665; Lehmann, J., et al., 1995. JBC 270, 12953.
Cantello, B., et al., 1994. Bioorg. Med. Chem. Lett. 4, 1181.
Product Information
CAS number155141-29-0
FormWhite powder
Hill FormulaC₁₈H₁₉N₃O₃S.C₄H₄O₄
Chemical formulaC₁₈H₁₉N₃O₃S.C₄H₄O₄
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥99% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Katalogové číslo GTIN
557366-10MG 04055977268027

Documentation

Rosiglitazone - CAS 155141-29-0 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

Rosiglitazone - CAS 155141-29-0 - Calbiochem Certificates of Analysis

TitleLot Number
557366

References

Přehled odkazů
Araki, T., et al. 2011. PPAR Res. 2011, 926438.
Sozio, M. S., et al. 2011. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G739.
Gerstein, H., et al. 2006. Drug 368, 9541.
Mohanty, P., 2004. Journ. Clin. Endocrin. & Metab. 89(6), 2728-2735.
Fryer, L., et al. 2002. J Biol Chem 277, 25226.
Goldberg, R., et al. 1999. Drug. 57, 921.
Young, P., et al. 1998. Journ. Pharm. Exp. Ther. 284, 751.
Willson, T., et al. 1996. J. Med. Chem.39, 665; Lehmann, J., et al., 1995. JBC 270, 12953.
Cantello, B., et al., 1994. Bioorg. Med. Chem. Lett. 4, 1181.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision10-August-2012 JSW
Synonyms5-[4-(2-[methyl(pyridin-2-yl)amino]ethoxy)benzyl]thiazolidine-2,4-dione, BRL49653, Avandia, PPAR Agonist X, PPARγ Agonist IX, AMPK Signaling Activator X
DescriptionA thiazolidinedione compound that acts as an anti-diabetic agent and serves as a potent and selective agonist of peroxisome proliferator-activated receptor-g (PPARg) (Kd ~40 nM) in fat cells. Shown to reduce fatty acid uptake and ameliorate lipid metabolism and insulin resistance in animal models of type II diabetes. Reported to activate both a1- and a2-containing AMPK complexes. Unlike troglitazone, it does not induce the activity of P4503A4. Significantly improves the differentiation of C3H10T1/2 stem cells into adipocytes. Shown to block estrogen synthesis by interfering with androgen binding to aromatase, but without affecting aromatase mRNA or protein expression.
FormWhite powder
CAS number155141-29-0
Chemical formulaC₁₈H₁₉N₃O₃S.C₄H₄O₄
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (100 mg/ml)
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesAraki, T., et al. 2011. PPAR Res. 2011, 926438.
Sozio, M. S., et al. 2011. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G739.
Gerstein, H., et al. 2006. Drug 368, 9541.
Mohanty, P., 2004. Journ. Clin. Endocrin. & Metab. 89(6), 2728-2735.
Fryer, L., et al. 2002. J Biol Chem 277, 25226.
Goldberg, R., et al. 1999. Drug. 57, 921.
Young, P., et al. 1998. Journ. Pharm. Exp. Ther. 284, 751.
Willson, T., et al. 1996. J. Med. Chem.39, 665; Lehmann, J., et al., 1995. JBC 270, 12953.
Cantello, B., et al., 1994. Bioorg. Med. Chem. Lett. 4, 1181.